Navigation Links
Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/3/2011

mon shareholders was $4.7 million, or $0.23 per diluted share, up 193.1% from $1.6 million, or $0.08 per diluted share, for the same period in 2010.

Balance Sheet:  As of September 30, 2011, cash and cash equivalents grew to $71.1 million, compared to $69.8 million at June 30, 2011. Total assets grew from $94.6 million on June 30, 2011 to $96.1 million as of September 30, 2011. Cumberland's total debt as of September 30, 2011, declined to $4.6 million from $5.8 million at June 30, 2011.

"Our financial performance in the third quarter of 2011 was strong, with our net income increasing 83% over the prior year period," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals.  "We achieved many milestones this quarter – including reaching an agreement to acquire the trademark and approved FDA registration for Kristalose, the appointment of Rick S. Greene as Chief Financial Officer, and the signing of new international product agreements – while maintaining strong sales of Acetadote and progressing our clinical trial programs. Our goal at Cumberland continues to be maintaining a financial discipline while delivering solid financial results and laying the ground work for future growth opportunities."

Based on its third quarter performance, Cumberland is reaffirming its full year 2011 revenue guidance of $51 - $55 million. This guidance represents the Company's best estimate of future results, which may be affected by factors described below in "Forward-Looking Statements."

Company Highlights Acetadote®

New Formulation

In January 2011, the U.S. Food and Drug Administration (FDA) approved Cumberland's supplemental new drug application (sNDA) for a new formulation of Acetadote, which was the result of a phase IV commitment the Company made to the FDA upon receipt of initial marketing approval of the product. The new formulation does not contain Ethylene diam
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
2. Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island
3. Cumberland Pharmaceuticals Appoints Lee Product Director
4. Cumberland Emerging Technologies and UT Research Foundation Sign License Agreement for New Technology
5. Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)
6. Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM)
7. Cumberland Pharmaceuticals Announces Pricing of Its Initial Public Offering of Common Stock
8. Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
10. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
11. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Look inside the ... items for the lab, from fluid handling to instruments ... to ship when you order. , Preferred Solutions ... , from the L/S® model for precise flow control ...
(Date:1/15/2014)... California , January 15, 2014 Oxford ... today announced the appointment of Thomas C Reynolds MD, PhD ... years, development experience gained in the biotechnology industry, most recently ... am delighted to welcome Tom at this transformative time for ...
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
(Date:1/15/2014)... More than 5 million Americans are currently ... seniors will die with Alzheimer’s or another dementia, according ... shocked many Americans into looking for ways to improve ... age-related cognitive disorders. Jonathan Weisman, president of Biohack Pure, ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2
... Space ... the eighth scientific payload for Astrogenetix, a commercial biotech company created to use microgravity ... ... off from NASA’s Kennedy Space Center this morning, carrying on board the eighth scientific ...
... , Full enrollment occurs five months ahead of schedule , ... /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced ... clinical study of its lead drug RVX-208. "The completion of ... months ahead of our original schedule, is a very exciting ...
... , , , , ... Feb. 8 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, ... China -based biotechnology company,focused on researching, developing, manufacturing and ... Panacor Bioscience Ltd. to develop and commercialize its,Nephoxil(R) pharmaceutical ...
Cached Biology Technology:Astrogenetix Continues MRSA Vaccine Development Onboard Endeavor 2Astrogenetix Continues MRSA Vaccine Development Onboard Endeavor 3Resverlogix Completes Patient Recruitment for ASSERT Trial 2Resverlogix Completes Patient Recruitment for ASSERT Trial 3Resverlogix Completes Patient Recruitment for ASSERT Trial 43SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 23SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 33SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 4
(Date:4/20/2014)... Neb., April 20, 2014 -- Using corn crop residue ... and can generate more greenhouse gases than gasoline, according ... Nature Climate Change . , The findings by a ... whether corn residue can be used to meet federal ... gas emissions. , Corn stover -- the stalks, leaves ...
(Date:4/18/2014)... have used techniques like X-ray crystallography and nuclear magnetic ... atomic structure of molecules, but such efforts have long ... quantities of a specific molecule and often in ordered ... all but impossible to peer into the structure of ... may soon be a thing of the past. ...
(Date:4/18/2014)... For the past 20 years, researchers have published ... research findings have suggested that soil organic carbon can ... tillage systems to no-till systems. However, there is a ... in corn and soybean rotations without cover crops, small ... carbon stocks at the published rates. , "Some studies ...
Breaking Biology News(10 mins):Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3MRI, on a molecular scale 2MRI, on a molecular scale 3Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4
... College of Medical Genetics (ACMG) will hold its 16th ... Sunday, March 29, 2009 at the Tampa Convention Center. ... healthcare is evolving at a dizzying pace and the ... opportunity for the medical and scientific media to learn ...
... then eating less may help you live longer. For ... of a new study predict the anti-aging strategy known ... dangerous exercise. "Today there are a lot of very ... this," said Raj Sohal, professor at the University of Southern ...
... A new strategy developed in the Neonatal and Infant ... premature infants and other newborns with severe swallowing difficulties ... study appearing in the February issue of the ... Nationwide Children,s were able to help 15 out of ...
Cached Biology News:Far-reaching genetics topics to be addressed: 2009 Annual Clinical Genetics Meeting, March 25-29 2Eating less may not extend life 2Crib-side studies help struggling newborns go home without feeding tubes 2Crib-side studies help struggling newborns go home without feeding tubes 3
Anti-Bcl-G (CT) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Rabbit polyclonal to Oct2, prediluted ( Abpromise for all tested applications). entrezGeneID: 5452 SwissProtID: P09086...
Anti-Mouse Reticular Fibroblast, Purified (Clone ER-TR7) (rat IgG2a)...
Biology Products: